ADTRAN
2.5.2024 14:01:30 CEST | Business Wire | Press release
Adtran today announced that a leading Canadian hydropower producer is using its Oscilloquartz grandmaster device combined with its optical cesium atomic clock to achieve new levels of precision, reliability and resilience in its power grid synchronization network. The deployment addresses the urgent need to implement the highest standards of protection against GNSS disruptions, including jamming and spoofing cyberattacks, and helps bolster North America’s energy resilience. Featuring multi-source protection, the enhanced timing architecture offers a zero-trust approach to positioning, navigation and timing (PNT), ensuring robust and accurate synchronization. It also seamlessly supports existing services, enabling a smooth transition from legacy timing to power grids with advanced PTP technology. For streamlined operations and assurance, the synchronization network is remotely managed through the Adtran Ensemble Controller with Sync Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502346533/en/
Adtran’s Oscilloquartz timing technology is playing a key role in protecting Canadian hydropower producer from GNSS cyberattacks. (Photo: Business Wire)
“It’s great to be helping another major utility to modernize its timing infrastructure and prepare for next-generation smart grid applications. The transition from traditional TDM to advanced packet-based synchronization marks a significant milestone for this forward-thinking power supplier. The solution will also strengthen its timing network against the growing dangers of relying solely on GNSS,” commented John Scherzinger, GM of Americas sales at Adtran. “The deployment of our advanced grandmaster clock enables the utility to extend reliable timing to Canada’s most remote regions. The superior stability and precision of our optical cesium clock are key to realizing levels of accuracy and resilience never seen before. What’s more, our Ensemble Sync Director system brings the benefits of centralized control, ensuring comprehensive monitoring and simplified operational management. This is essential for maintaining the reliability and security of the utility’s extensive and often remotely located network.”
By enhancing its timing framework with Adtran’s Oscilloquartz solution, the hydroelectric producer is ensuring it maintains the highest standards of cybersecurity and energy reliability in its critical infrastructure. The deployment will also improve the stability and security of the energy supply across Canada and the US. The new solution includes Adtran’s OSA 3350 ePRC+ combined with its highly versatile OSA 5422 to provide the highest precision, stability and resilience against GNSS vulnerabilities. Featuring an all-digital design, the OSA 3350 ePRC+ utilizes optical-pumping techniques, guaranteeing timing accuracy and optimal stability for over a decade – twice the lifespan of conventional cesium clocks. Together with the OSA 5422, the solution future-proofs the utility’s timing network and assures compliance with governmental regulations. It also fortifies security and underscores the renewable energy utility’s commitment to maintaining a continuous, secure power supply.
“This leading Canadian power supplier is renowned for its dedication to innovation. Its choice to adopt our technology highlights both the impact of our solution and its significance on a global scale. By transitioning its substation network from traditional TDM to advanced packet-based synchronization, it’s setting a precedent for the entire industry to follow,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our solution offers robust defense against GNSS vulnerabilities and ensures adherence to stringent industry regulations. Through our ongoing support, the utility is reinforcing its dedication to enhancing both resilience and reliability – elements that are fundamental for fulfilling PNT requirements. This is crucial for safeguarding the integrity of critical network infrastructure, ensuring a consistent and dependable energy future for all.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502346533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
